Clinical trials: Solid Malignant Tumor
Solid Tumor
A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment and nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-B16D1 in…
- Trial name
- NCT06475131
- Testing
- BL-B16D1
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Or Metastatic Solid Tumor Malignancies
A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.
This is a first in human, open-label, single-arm, multicenter dose escalation and expansion Phase 1 study of SHR-A2102 in patients with advanced or metastatic solid tumors.
- Trial name
- NCT05735275
- Testing
- SHR-A2102
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Advance Solid Tumors, Lymphoma, Non-Hodgkin
Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers
Evaluate the safety and tolerability of JMBI-001 in adults with MYC-positive advanced cancers.
- Trial name
- PANGU-1 (NCT07864701)
- Testing
- JMBI-001 Tablets
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Chengdu Anticancer Bioscience, Ltd.
Pan Tumor
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
The purpose of this study is to demonstrate the clinical activity of nivolumab in combination with ipilimumab in multiple types of tumors based on their Tumor Mutational Burden status.
- Trial name
- CheckMate 848 (NCT03668119)
- Testing
- Nivolumab, Ipilimumab
- Where
- 60 sites in United States, Argentina and 15 more
- Volunteers
- 212 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor, Metastatic Cancer
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the…
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer
- Trial name
- NCT04464967
- Testing
- SNK01, Trastuzumab, Cetuximab
- Sponsor
- NKGen Biotech, Inc.
Malignant Neoplasm
A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer
NBM-BMX is an orally available new chemical entity to inhibit HDAC8 activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise.
- Trial name
- NCT03808870
- Testing
- NBM-BMX softgel capsules
- Where
- 2 sites in Taiwan
- Volunteers
- 21 people
- Sponsor
- NatureWise Biotech & Medicals Corporation
Ovarian Cancer
Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy
The primary objectives of this study are to investigate the safety and tolerability of magrolimab in combination with avelumab in participants with advanced solid tumors and to confirm the safety and tolerability of this…
- Trial name
- NCT03558139
- Testing
- Magrolimab, Avelumab
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Gilead Sciences
Advanced Solid Tumors
Study on the Safe Dosage and Therapeutic Effect of the Drug YY2201 Tablets on Patients With Advanced Cancer
The goal of this clinical trial is to assess the safety and tolerability of YY2201 in participants with advanced solid tumors. The main questions it aims to answer are: What medical problems do participants have when taking drug…
- Trial name
- NCT06976931
- Testing
- YY2201
- Volunteers
- 42 people
- Sponsor
- Jiangsu YaYao Biotechnology Co., Ltd.
Malignant Neoplasm of Digestive System
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors
This study is an open-label Phase 1, First in Human trial of DR30303, a recombinant humanized monoclonal antibody that targets Claudin18.2 (CLDN18.2).
- Trial name
- NCT05639153
- Testing
- DR30303
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Solid Tumor
A Study of LY3415244 in Participants With Advanced Solid Tumors
The goal of this study is to evaluate the safety of LY3415244, a PD-L1/TIM-3 bispecific antibody, administered as monotherapy to participants with advanced solid tumors.
- Trial name
- NCT03752177
- Testing
- LY3415244
- Where
- 6 sites in United States, Belgium and 1 more
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Lung Cancer, Non-Small Cell
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
- Trial name
- NCT00866528
- Testing
- pazopanib, paclitaxel
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Patients With Advanced Solid Tumors
Safety and Tolerability of Intravenous Administration of ICVB-1042
Study to evaluate the safety and tolerability of intravenous ICVB-1042
- Trial name
- ICVB-1042 (NCT05904236)
- Testing
- Treatment with ICVB-1042 administered intravenously
- Where
- 10 sites in United States
- Volunteers
- 17 people
- Sponsor
- IconOVir Bio
Solid Tumor
Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors
An open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 as single-agent therapy and as combination therapy with temozolomide in patients with advanced solid tumors.
- Trial name
- NCT00920595
- Testing
- CEP-9722
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 26 people
- Sponsor
- Cephalon
Solid Tumor, Adult
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
The drug that will be investigated in the study is GEN1053. GEN1053 is an antibody designed to (re)activate and increase antitumor immunity.
- Trial name
- NCT05435339
- Testing
- GEN1053
- Where
- 5 sites in United States, Spain
- Volunteers
- 31 people
- Sponsor
- Genmab
Advanced Solid Tumor
A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor
This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AEs) and serious adverse events (SAEs) , pharmacokinetic parameters and antitumor effect of TQB3823 tablets in Chinese adult…
- Trial name
- NCT05021367
- Testing
- TQB3823 tablets
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Solid Tumor
A Study of AK131 in Patients With Advanced Solid Tumors
This is a phase Ia/Ib study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK131 in advanced solid tumor patients
- Trial name
- NCT06166888
- Testing
- AK131
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Akeso
CRC
Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Trial name
- NCT07511972
- Testing
- NGM707 plus pembrolizumab
- Sponsor
- NGM Biopharmaceuticals, Inc
Childhood Solid Tumor
Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood
This is an un-blinded Phase 1 study in which 21 patients suffering from solid advanced paediatric malignancies (14 sarcoma and 7 non-sarcoma patients) are treated with AV0113, an anti-tumour immune therapy with autologous…
- Trial name
- NCT02533895
- Testing
- AV0113 DC-CIT, Data evaluation
- Where
- 2 sites in Austria
- Volunteers
- 67 people
- Sponsor
- Activartis Biotech
Solid Tumor Malignancies, Malignant Mesothelioma (MM)
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
This study is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of the TEAD inhibitor TYK-01054 capsules in patients with locally advanced or metastatic advanced solid tumors
- Trial name
- NCT07282873
- Testing
- TYK-01054
- Where
- China
- Volunteers
- 219 people
- Sponsor
- TYK Medicines, Inc
Advanced Solid Tumor
A Phase I Study of BR790 in Subjects With Advanced Solid Tumors
The purpose of the study was to evaluate the safety and tolerability of BR790 tablets as an oral monotherapy in subjects with advanced solid tumors, and to determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD)…
- Trial name
- NCT04891653
- Testing
- BR790
- Volunteers
- 48 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.